A new baby-spacer device for aerosolized bronchodilator administration in infants with bronchopulmonary disease

The response of salbutamol (Ventolin, Glaxo), topically administered from a metered dose inhaler (MDI) through a new baby-spacer-device (Babyhaler, Glaxo) was studied in 14 infants (8 wheezy infants, 3 infants with cystic fibrosis and 3 infants after respiratory distress syndrome), age 2.9-18.8 mont...

Full description

Saved in:
Bibliographic Details
Published in:European journal of pediatrics 1992, Vol.151 (1), p.57-60
Main Authors: KRAEMIER, R, BIRRER, P, MODELSKA, K, CASAULTA AEBISCHER, C, SCHÖNI, M. H
Format: Article
Language:English
Subjects:
Albuterol - administration & dosage
Biological and medical sciences
Cystic Fibrosis - complications
Humans
Infant
Infant, Newborn
Medical sciences
Pharmacology. Drug treatments
Respiratory Distress Syndrome, Newborn - complications
Respiratory system
Respiratory Therapy - instrumentation
Respiratory Tract Diseases - drug therapy
Respiratory Tract Diseases - etiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The response of salbutamol (Ventolin, Glaxo), topically administered from a metered dose inhaler (MDI) through a new baby-spacer-device (Babyhaler, Glaxo) was studied in 14 infants (8 wheezy infants, 3 infants with cystic fibrosis and 3 infants after respiratory distress syndrome), age 2.9-18.8 months. Changes in thoracic gas volume (TGV) as an estimate of pulmonary hyperinflation and changes in airway conductance (Gaw) as an estimate of bronchial obstruction were assessed by whole-body plethysmography. After baseline measurements, 1 puff of 100 micrograms salbutamol was given repeatedly at 5 min intervals until 600 micrograms have been inhaled and TGV and Gaw were measured after each inhalation at 5, 10, 15, 20, 25 and 30 min. Significant improvement in lung function was achieved in 57.1% of infants after 400 micrograms and in 92.9% of infants after 600 micrograms salbutamol. The study shows usefulness of bronchodilator treatment in infants with bronchopulmonary disease by a system with a MDI and baby-spacer-device. However a special dose-time relationship must be respected.
ISSN:0340-6199
1432-1076
DOI:10.1007/BF02073894